慢乙肝抗病毒治疗热点难点耐药和复发再治创新.pptVIP

* * * * * HBeAg, hepatitis B e antigen; LAM, lamivudine; LdT, telbivudine; PCR, polymerase chain reaction; PegIFN, peginterferon; QL, quantification limit. This slide shows that early and profound suppression of viral replication is predictive of a greater sustained response. On the Y axis is the percentage of patients who are PCR negative or HBV DNA undetectable at follow?up. The X axis is divided into 3 parts. The left-most part of the graph represents HBeAg-negative patients undergoing 72 weeks of peginterferon alfa-2a. This part of the graphic shows that HBV DNA level at the early time poi